Skip to main content

Table 4 Mean change in central systolic blood pressure (mmHg) after EMPA therapy separated according to median of different variables

From: How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Variable

Age

HbA1c

Copeptin

Heart rate

LDL-cholesterol

Uric acid

Systolic BP

hsCRP

≥ median

− 6.23 ± 11.2

− 6.46 ± 11.1

− 8.94 ± 10.2

− 4.49 ± 9.89

− 5.50 ± 12.1

− 6.21 ± 9.54

− 5.13 ± 10.6

− 4.21 ± 10.3

< median

− 3.76 ± 9.83

− 3.61 ± 9.97

− 1.78 ± 9.83

− 5.48 ± 11.3

− 4.51 ± 9.06

− 3.76 ± 11.45

− 4.88 ± 10.7

− 5.77 ± 10.9

p-value

0.378

0.308

0.009

0.724

0.724

0.378

0.928

0.576

  1. Data are given as mean ± SD
  2. hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24 h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood pressure